Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 769

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 3
Chunk 769
---
Georgetown University Medical Center, where he designed and managed the faculty compensation system, while managing the finances and
information systems for the department. His financial management experience in publicly held companies includes Director of Managed Care
Reimbursement for Critical Care America from 1990 to 1993 and Regional Controller for Laboratory Corporation of America (LabCorp) from
1993 to 1996. His responsibilities at both companies included extensive financial management related to mergers, acquisitions, and start-up
operations. Mr. Vander Hoek holds a Master’s in Health Services Administration from The George Washington University and a Bachelor
of Arts in Biology and Psychology from Hope College.

70

Peter
Dritschilo has served as our President and Chief Operating Officer since Shuttle was formed in December 2012. He also served as our
Chief Financial Officer until 2019. Mr. Dritschilo has more than 25 years of business management experience in medical services and cancer
treatment. He has held administrative positions with Medstar-Rad America from 2001 to 2005, Georgetown University 2005 to 2006, Prince
William Hospital and the Fauquier Hospital Cancer Center 2006 to 2011 and Inova Health System’s Schar Cancer Institute from 2011
to 2018. In 2014, Mr. Dritschilo filed for Chapter 7 bankruptcy protection due to the failure of a personal business venture. Mr. Dritschilo
graduated from Georgetown University and received his MBA from the George Washington University.

Mira
Jung, Ph.D., a co-founder of our Company, has served as our Chief Scientific Officer for Biology since December 2012, and was a member
of our board of directors from our formation in December 2012 until 2019. Since 2004, Dr. Jung has served as Professor of Radiation Medicine
and Microbiology at Georgetown University Medical School. With over 30 years of experience in molecular radiation biology research, she
is an expert in mechanisms of radiation resistance and on the roles of HDAC inhibitors in modifying the radiation response. Dr. Jung’s
research has been funded by NIH and the DOD leading to 100+ publications and nine patents granted by the USPTO, including the first reports
of HDAC inhibitor drug classes modifying cancer cell radiation resistance and protecting normal tissues from radiation damage. Dr. Jung
holds an MA degree and a PhD in Microbiology and Molecular Virology from the University of Kansas